Truist Financial
FOLD

Truist Financial’s Amicus Therapeutics FOLD Stock Holding History

Truist Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,308
Closed -$231K – 2794
2025
Q3 		$231K Buy
29,308
+6,788
+30% +$48.3K ﹤0.01% 2472
2025
Q2 		$129K Sell
22,520
-2,471
-10% -$15.9K ﹤0.01% 2478
2025
Q1 		$204K Buy
24,991
+7,203
+40% +$66.7K ﹤0.01% 2354
2024
Q4 		$168K Sell
17,788
-1,235
-6% -$12.8K ﹤0.01% 2416
2024
Q3 		$203K Buy
19,023
+4,560
+32% +$49.7K ﹤0.01% 2342
2024
Q2 		$143K Buy
14,463
+167
+1% +$1.71K ﹤0.01% 2559
2024
Q1 		$168K Buy
+14,296
New +$183K ﹤0.01% 2513

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Truist Financial's FOLD Position: Q4 2025 in Review

Truist Financial sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 29,308 shares — an estimated $231K sold.

Truist Financial first reported a position in FOLD in Q1 2024 and held it in 7 quarters. The position peaked at $231K in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Truist Financial reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Truist Financial sold 29,308 Amicus Therapeutics shares in Q4 2025, an estimated $231K.
  • Truist Financial first reported a position in Amicus Therapeutics in Q1 2024 and held it in 7 quarters.
  • Truist Financial's Amicus Therapeutics position peaked at $231K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.